Cōntego™ is being developed for the treatment of metastatic melanoma, and ovarian, breast and colorectal cancers.
- In-patient therapy.
- Reimbursement managed by hospital administrators/reimbursement staff.
- Therapy supported by strong balance sheets of major medical centers.
- Clearly demarcated Stage IV patient populations refractory to all FDA approved therapies.
- Clear regulatory pathway with potential product launch within four years for the treatment of metastatic melanoma.